Treatment with N-tosyl-l-phenylalanine chloromethyl ketone after the onset of collagen-induced arthritis reduces joint erosion and NF-kappaB activation

European Journal of Pharmacology
Jin ChoiDae-Myung Jue

Abstract

N-tosyl-l-phenylalanine chloromethyl ketone (TPCK) is known to inhibit NF-kappaB activation and the expression of inflammation mediators in cultured cells. We measured the potential of TPCK to inhibit the pathogenesis of collagen-induced arthritis by blocking NF-kappaB activation. Arthritis was induced in DBA/1J mice by the injection of bovine type II collagen in adjuvant on days 0 and 14. Mice received either TPCK (3 or 10 mg/kg, i.p.) or vehicle three times a week for 3 weeks starting on day 21. TPCK moderately reduced clinical disease activity scores, whereas it markedly suppressed histological indications of joint destruction. In vitro production of tumor necrosis factor-alpha, interleukin-6, and monocyte chemotactic protein-1 from lipopolysaccharide-stimulated spleen cells was also reduced by in vivo treatment with TPCK. Proliferation of cells isolated from spleen or draining lymph nodes and production of interferon-gamma and interleukin-17 in response to stimulation with type II collagen was decreased by TPCK. Moreover, nuclear NF-kappaB activity induced by collagen immunization was significantly reduced in mice treated with TPCK. Finally, osteoclast differentiation of bone marrow cells induced by macrophage colony-stimul...Continue Reading

References

May 25, 1995·Biochemical and Biophysical Research Communications·W W WangL J Ignarro
Dec 20, 1994·Proceedings of the National Academy of Sciences of the United States of America·S MiyamotoI M Verma
Mar 1, 1995·Molecular and Cellular Biology·I AlkalayY Ben-Neriah
Dec 6, 1994·Proceedings of the National Academy of Sciences of the United States of America·T S FincoA S Baldwin
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·P J ChiaoI M Verma
Dec 1, 1995·Arthritis and Rheumatism·M L HandelE M Gravallese
Apr 10, 1997·The New England Journal of Medicine·P J Barnes, M Karin
Nov 14, 1997·Nature Medicine·V IotsovaR Bravo
Jan 1, 1997·Life Sciences·L K MyersA H Kang
Feb 7, 1998·Genes & Development·G FranzosoU Siebenlist
Jul 13, 1999·Journal of Korean Medical Science·D M JueJ Y Jeong
Mar 10, 2000·European Journal of Pharmacology·M H LeBlancJ D Fratkin
Jul 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·D M GerlagG S Firestein
Feb 15, 2001·Arthritis Research·W B van den Berg
Mar 22, 2001·The New England Journal of Medicine·E H Choy, G S Panayi
Jan 15, 2003·Experimental & Molecular Medicine·Mi-Sun ByunDae-Myung Jue
May 16, 2003·Nature·William J BoyleDavid L Lacey
Jun 14, 2003·Drug News & Perspectives·E Lubberts, W B van den Berg
Nov 11, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·John C ClohisyYousef Abu-Amer
Aug 31, 2004·Arthritis and Rheumatism·Gary S Firestein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here